Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Alembic Pharmaceuticals gets USFDA nod for ophthalmic solution

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Olopatadine Hydrochloride ophthalmic solution USP, 0.1 percent, Alembic Pharmaceuticals said in a filing to BSE.

December 10, 2018 / 11:43 AM IST
Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Alembic Pharmaceuticals said it has received approval from the US health regulator for Olopatadine Hydrochloride ophthalmic solution, used to treat allergic conjunctivitis.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Olopatadine Hydrochloride ophthalmic solution USP, 0.1 percent, Alembic Pharmaceuticals said in a filing to BSE.

The approved product is therapeutically equivalent to the reference listed drug product (RLD) Patanol ophthalmic solution, 0.1 percent, of Novartis Pharmaceuticals Corporation, the company added.

Quoting IQVIA data, Alembic Pharma said Olopatadine Hydrochloride ophthalmic solution has an estimated market size of USD 61 million for 12 months ending December 2017.

The company said it currently has 83 ANDA approvals from USFDA.

PTI
first published: Dec 10, 2018 11:36 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347